These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15798381)

  • 1. Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era.
    Campo RE; Campo CE; Peter G; Zuleta J; Wahlay NA; Cleary T; Kolber MA; Dickinson GM
    AIDS Patient Care STDS; 2005 Mar; 19(3):141-9. PubMed ID: 15798381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
    Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006.
    Steenhoff AP; Wood SM; Rutstein RM; Wahl A; McGowan KL; Shah SS
    Pediatr Infect Dis J; 2008 Oct; 27(10):886-91. PubMed ID: 18776825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era.
    Munier AL; de Lastours V; Porcher R; Donay JL; Pons JL; Molina JM
    Int J STD AIDS; 2014 Dec; 25(14):1022-8. PubMed ID: 24676129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease.
    Grau I; Ardanuy C; Liñares J; Podzamczer D; Schulze MH; Pallares R
    HIV Med; 2009 Sep; 10(8):488-95. PubMed ID: 19459987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.
    Jordano Q; Falcó V; Almirante B; Planes AM; del Valle O; Ribera E; Len O; Pigrau C; Pahissa A
    Clin Infect Dis; 2004 Jun; 38(11):1623-8. PubMed ID: 15156452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.
    Harboe ZB; Larsen MV; Ladelund S; Kronborg G; Konradsen HB; Gerstoft J; Larsen CS; Pedersen C; Pedersen G; Obel N; Benfield T
    Clin Infect Dis; 2014 Oct; 59(8):1168-76. PubMed ID: 25038114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalizations for invasive pneumococcal disease among human immunodeficiency virus-1 infected children, adolescents and young adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine.
    Kourtis AP; Ellington S; Bansil P; Jamieson DJ; Posner SF
    Pediatr Infect Dis J; 2010 Jun; 29(6):561-3. PubMed ID: 20094005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994.
    Hibbs JR; Douglas JM; Judson FN; McGill WL; Rietmeijer CA; Janoff EN
    Clin Infect Dis; 1997 Aug; 25(2):195-9. PubMed ID: 9332509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in cancer patients.
    Garcia-Vidal C; Ardanuy C; Gudiol C; Cuervo G; Calatayud L; Bodro M; Duarte R; Fernández-Sevilla A; Antonio M; Liñares J; Carratalà J
    J Infect; 2012 Dec; 65(6):521-7. PubMed ID: 22954752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance.
    Arifeen SE; Saha SK; Rahman S; Rahman KM; Rahman SM; Bari S; Naheed A; Mannan I; Seraji MH; Ahmed NU; Hassan MS; Huda N; Siddik AU; Quasem I; Islam M; Fatima K; Al-Emran H; Brooks WA; Baqui AH; Breiman RF; Sack D; Luby SP
    Clin Infect Dis; 2009 Mar; 48 Suppl 2():S103-13. PubMed ID: 19191605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program.
    Nunes MC; von Gottberg A; de Gouveia L; Cohen C; Kuwanda L; Karstaedt AS; Klugman KP; Madhi SA
    PLoS One; 2011; 6(11):e27929. PubMed ID: 22140487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
    Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
    Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
    Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased incidence of pneumococcal bloodstream infections.
    Rodríguez-Créixems M; Bertó J; Muñoz P; Alonso R; Alcalá L; Bouza E
    Pediatr Infect Dis J; 2003 Jul; 22(7):661-3. PubMed ID: 12886897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-related pneumococcal lung disease: does highly active antiretroviral therapy or bacteremia modify radiologic appearance?
    Rizzi EB; Schininá V; Rovighi L; Cristofaro M; Bordi E; Narciso P; Bibbolino C
    AIDS Patient Care STDS; 2008 Feb; 22(2):105-11. PubMed ID: 18260801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.
    Watson M; Roche P; Bayley K; Bell JM; Collignon P; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Smith HV; Brown M; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2004; 28(4):455-64. PubMed ID: 15745392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive pneumococcal disease in Costa Rican children: a seven year survey.
    Ulloa-Gutierrez R; Avila-Aguero ML; Herrera ML; Herrera JF; Arguedas A
    Pediatr Infect Dis J; 2003 Dec; 22(12):1069-74. PubMed ID: 14688567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.